Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Zaks on the JAK2 Inhibitor SAR302503 in Myelofibrosis

January 21st 2013

Tal Zaks, MD, PhD, Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.

Dr. Cervantes Discusses COMFORT-II Long-Term Data

January 10th 2013

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.

Dr. Barbui on Hematocrit Levels in Polycythemia Vera

December 9th 2012

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

Dr. Mesa Discusses the COMFORT Ruxolitinib Trials

April 9th 2012

Dr. Ruben Mesa, from Mayo Clinic, Arizona, Discusses the COMFORT Ruxolitinib Trials

Dr. Mesa Discusses JAK Inhibitors for Myelofibrosis

March 2nd 2012

Dr. Ruben Mesa from the Mayo Clinic in Arizona Discusses JAK Inhibitors for Myelofibrosis

Ruxolitinib Gains FDA Approval for Bone Marrow Disease

November 17th 2011

The FDA approved ruxolitinib (Jakafi) as the first drug to specifically treat patients with myelofibrosis, a bone marrow disease.

Investigational Agent Provides Hope for Patients With Myelofibrosis

August 15th 2011

Treating myelofibrosis with the investigational JAK inhibitor ruxolitinib holds promise.

Ruxolitinib Results Promising in 2 Myelofibrosis Studies

July 25th 2011

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

NEXT PAGE
PREVIOUS PAGE